Obsidio Therapeutics is a late preclinical stage company with a lead asset in IND development. OBT-893 is a first in class drug that targets solid tumors in an unprecedented and sustainable way. Unlike standard targeted therapies, OBT-893 is effective against tumors with diverse driver mutations (e.g. Kras, PTEN, P53) and metabolic profiles. This broad activity stems from OBT-893’s ability to simultaneously block both primary and adaptive nutrient sourcing pathways. In multiple animal tumor models OBT-893 has been shown to be broadly effective and cancer selective overcoming the resistance conferred by tumor heterogeneity and limiting the development of acquired resistance.
Add to my schedule
Create your personal schedule through the official app, Whova!Get Started